Nov 6, 2025 07:52AM Entrada Therapeutics (TRDA) files $400M mixed shelf

Sep 17, 2025 04:04AM Goldman Sachs Starts Entrada Therapeutics (TRDA) at Early-Stage Biotech

Sep 5, 2025 07:00AM Entrada Therapeutics awards $50,000 grants to two Duchenne organizations

Aug 7, 2025 08:45AM Entrada Therapeutics (TRDA) PT Lowered to $17 at Roth/MKM

Aug 6, 2025 07:56AM Entrada Therapeutics, Inc. (TRDA) Misses Q2 EPS by 22c

Jun 3, 2025 07:03AM Entrada Therapeutics (TRDA) Appoints Maha Radhakrishnan to its Board

Jun 2, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Entrada Therapeutics (TRDA)

May 28, 2025 07:01AM Entrada Therapeutics (TRDA) Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne

May 8, 2025 04:54PM Entrada Therapeutics, Inc. (TRDA) Tops Q1 EPS by 31c

Mar 31, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Entrada Therapeutics (TRDA)

Mar 25, 2025 06:51AM William Blair Reiterates Outperform Rating on Entrada Therapeutics (TRDA)

Mar 24, 2025 01:50PM Oppenheimer Reiterates Outperform Rating on Entrada Therapeutics (TRDA)

Mar 24, 2025 09:15AM Roth/MKM on Entrada Therapeutics (TRDA): 'we remain bullish on Entrada’s DMD programs'

Mar 24, 2025 07:01AM Entrada Therapeutics (TRDA) Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201

Mar 3, 2025 06:01AM Entrada Therapeutics, Inc. (TRDA) Tops Q4 EPS by 70c

Feb 28, 2025 12:43AM Oppenheimer Reiterates Outperform Rating on Entrada Therapeutics (TRDA)

Feb 25, 2025 06:49AM H.C. Wainwright Reiterates Buy Rating on Entrada Therapeutics (TRDA)

Feb 24, 2025 07:00AM Entrada Therapeutics (TRDA) Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 4, 2025 06:41AM H.C. Wainwright Reiterates Buy Rating on Entrada Therapeutics (TRDA)

Feb 3, 2025 07:00AM Entrada Therapeutics (TRDA) Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201

Dec 6, 2024 08:41AM Roth/MKM Starts Entrada Therapeutics (TRDA) at Buy

Nov 6, 2024 07:44AM Entrada Therapeutics (TRDA) PT Raised to $28 at Oppenheimer

Nov 6, 2024 06:48AM Entrada Therapeutics (TRDA) PT Raised to $20 at H.C. Wainwright

Nov 5, 2024 04:08PM Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 38c

Oct 9, 2024 07:01AM Entrada Therapeutics (TRDA) Presents New Data Supporting its Expanding Duchenne Franchise

Sep 24, 2024 07:03AM Entrada Therapeutics (TRDA) Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Aug 14, 2024 12:14PM TD Cowen Reiterates Buy Rating on Entrada Therapeutics (TRDA)

Aug 13, 2024 07:51AM Entrada Therapeutics, Inc. (TRDA) Tops Q2 EPS by $1.19

Jun 25, 2024 06:39AM Entrada Therapeutics (TRDA) PT Lowered to $18 at H.C. Wainwright

Jun 24, 2024 02:09PM TD Cowen Reiterates Buy Rating on Entrada Therapeutics (TRDA)

Jun 24, 2024 07:15AM Entrada Therapeutics (TRDA) Announces $100 Million Registered Direct Offering

Jun 24, 2024 06:00AM Entrada Therapeutics (TRDA) Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial